Liposomal irinotecan in combination with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (OX) (NALIRIFOX regimen) is tolerable and possesses antitumour activity in previously untreated patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), according to long-term follow-up results of a phase I/II trial presented at WCGC 2020.
The novel combination regimen comprising the immune checkpoint inhibitors (ICIs) durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) showed a favourable safety profile and clinical activity for advanced hepatocellular carcinoma (HCC), according to detailed safety data presented at ESMO GI 2020.
The combination of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) improves objective response rate (ORR) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) in the first-line setting, according to the ANCHOR CRC* trial presented at ESMO GI 2020.
The novel switch-control tyrosine kinase inhibitor ripretinib delivered a clinically meaningful benefit for patients with gastrointestinal stromal tumours (GISTs) following crossover from placebo, and had a safety profile consistent with that observed in the double-blind phase, according to the results of the crossover analysis of the INVICTUS trial presented at ESMO GI 2020.
Older patients (aged ≥65 years) with unresectable hepatocellular carcinoma (HCC) may derive greater survival benefit with an atezolizumab + bevacizumab combination compared with sorafenib, according to results of a subgroup analysis of the IMbrave150 trial presented at ESMO GI 2020.
A subgroup analysis of Asian patients enrolled in the CheckMate 040* trial presented at ESMO GI 2020 showed that the nivolumab + ipilimumab (NIVO + IPI) combination regimen had an efficacy and safety profile that was similar to that of the overall population.
In patients with advanced hepatocellular carcinoma (HCC), first-line treatment with nivolumab may confer greater overall survival (OS) than sorafenib, according to updated results of the phase III CheckMate 459* study.
Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.
Irinotecan monotherapy may be as effective as an irinotecan-containing doublet therapy for second-line chemotherapy (CT) for individuals with advanced gallbladder cancers (GBCs) who are progressing on first-line CT, the phase II GB SELECT trial has shown.
A lower baseline carcinoembryonic antigen (CEA) is associated with better overall survival (OS) in patients receiving treatment with encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic CRC (mCRC), according to a subanalysis of BEACON CRC presented during the 2020 ESMO GI Meeting.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.